Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FTO | Q9C0B1 | 2/20 | 0.77 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.68 |
| ▸ | PABPC1 | P11940 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | POLB | P06746 | 2/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | RAD52 | P43351 | 1/20 | 0.65 |
| ▸ | RECQL | P46063 | 1/20 | 0.65 |
| ▸ | RAB9A | P51151 | 1/20 | 0.65 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.65 |
| ▸ | HEXA | P06865 | 3/20 | 0.61 |
| ▸ | HEXB | P07686 | 3/20 | 0.61 |
| ▸ | OGA | O60502 | 1/20 | 0.61 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.60 |
| ▸ | NGFR | P08138 | 1/20 | 0.60 |
| ▸ | CA12 | O43570 | 3/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9504090 | 0.97 | FTO (0.76) | FTOSIRT1PABPC1MEN1KMT2A | |
| SCHEMBL9501837 | 0.96 | FTO (0.82) | FTOSIRT1PABPC1MEN1KMT2A | |
| SCHEMBL8984579 | 0.95 | FTO (0.80) | FTOSIRT1PABPC1MEN1KMT2A | |
| SCHEMBL12502144 | 0.94 | FTO (0.75) | FTOSIRT1PABPC1MEN1KMT2A | |
| SCHEMBL12660529 | 0.93 | FTO (0.71) | FTOSIRT1PABPC1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL5747370 | 0.92 | FTO (0.72) | FTOSIRT1PABPC1MEN1KMT2A | |
| SCHEMBL12660575 | 0.91 | FTO (0.65) | FTOSIRT1PABPC1MEN1KMT2A | |
| SCHEMBL12660530 | 0.90 | FTO (0.69) | FTOSIRT1PABPC1MEN1KMT2A | |
| SCHEMBL26773419 | 0.90 | FTO (0.76) | FTOSIRT1PABPC1MEN1KMT2A | |
| SCHEMBL8984832 | 0.89 | FTO (0.74) | FTOSIRT1PABPC1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947839-B2 | Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use | GENENTECH, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-7947839-B2 | Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use | GENENTECH, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| WO-2007064345-A9 | HETEROCYCLIC-SUBSTITUTED BIS-1,8 NAPHTHALIMIDE COMPOUNDS, ANTIBODY DRUG CONJUGATES, AND METHODS OF USE | GENENTECH INC (US) | 2007-07-12 | — | — | WO | disclosed |
| US-20070134243-A1 | Antibody drug conjugates and methods | GENENTECH, INC. | 2007-06-14 | — | — | US | disclosed |
| US-20070134243-A1 | Antibody drug conjugates and methods | GENENTECH, INC. | 2007-06-14 | — | — | US | disclosed |
| EP-0714387-B1 | NEW BIS-NAPHTHALIMIDES FOR THE TREATMENT OF CANCER | BASF AG (DE) | 1998-05-27 | — | — | EP | disclosed |
| EP-0714387-A1 | NEW BIS-NAPHTHALIMIDES FOR THE TREATMENT OF CANCER | BASF AKTIENGESELLSCHAFT (DE) | 1996-06-05 | — | — | EP | disclosed |
| WO-1995005365-A1 | NEW BIS-NAPHTHALIMIDES FOR THE TREATMENT OF CANCER | BASF AKTIENGESELLSCHAFT (DE) | 1995-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070134243-A1 | Antibody drug conjugates and methods | BOD1L1, MKI67, CCNI | FTO 4755/4885SIRT1 2328/4885PABPC1 1679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.